Entering text into the input field will update the search result below

Teva prevails in Narcan patent dispute with Opiant

  • Opiant Pharmaceuticals (NASDAQ:OPNT) reports that a New Jersey district court has ruled in favor of Teva Pharmaceutical Industries (NYSE:TEVA) in a patent infringement lawsuit brought by Opiant in response to Teva's U.S. application seeking approval to market a generic version of opioid overdose med Narcan (naloxone HCl) Nasal Spray.
  • The company says commercial partner Emergent BioSolutions (NYSE:EBS) intends to appeal the decision.
  • Update: OPNT is down 29% premarket on Monday, June 8, and EBS is down 10%, both on light volume. TEVA is up 1%, also on light volume.

Recommended For You

Related Stocks

SymbolLast Price% Chg
TEVA
--
EBS
--
OPNT
--